EFFECTS OF NICOTINIC ACID AND SEVELAMER ON HYPERPHOSPHATEMIA IN THE HEMODIALYSIS PATIENTS: A DOUBLE BLIND CLINICAL TRIAL

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

AMERIAN MONERE; ZOLFAGHARI POUNEH; SOHRABI MOHAMMAD BAGHER; NIKKHESLAT NASIM; YAHYAEI ELAHEH; HOSSAIN ZARGHARI SIMA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: KNOWLEDGE AND HEALTH Year:2016 | Volume:1 | Issue:1 Page(s): 62-68

Download Full-Text

Persian Verion

View:

1,100

Download:

Cites:

Information Journal Paper

Title

EFFECTS OF NICOTINIC ACID AND SEVELAMER ON HYPERPHOSPHATEMIA IN THE HEMODIALYSIS PATIENTS: A DOUBLE BLIND CLINICAL TRIAL

Author(s)

Keywords

NICOTINIC ACIDQ2

SEVELAMER CARBONATEQ2

HYPERPHOSPHATEMIAQ2

HEMODIALYSISQ3

Abstract

Introduction: Control of the phosphorus in dialysis’ patients is very important and can be done in many ways. The purpose of the study is to determine the effect of NICOTINIC ACID (Niacin) and Sevelamer on the serum phosphorus of HEMODIALYSIS patients.Methods: This double-blind randomized clinical trial study includes two groups: 60 patients (taking Niacin) and 60 patients control groups (taking Sevelamer).Niacin dose was increasing monthly in three steps from 200 to 600 mg and Sevelamer from 400 to 1200 mg. Serum phosphorus was measured in the both groups and the results were compared. In this study P<0.05 was significant.Results: A total of 120 patients attending in this study, mean age of case group were 51.5 ± 21.3 years and control group was 50.7 ± 22.5 years that no have difference. Phosphor level in starter study in case group was 6.67±1.37 mg/dl and control group was 6.77±0.95 mg/dl that no has difference. Niacin significantly decreased the blood phosphorus levels (P<0.001) that with increasing the dose of niacin, this decreasing was more than Sevelamer.Conclusion: NICOTINIC ACID can decrease serum phosphorous; however, it is need a longer trial study for determining the most effective doses of the NICOTINIC ACID.

Cites

No record.

References

No record.

Cite

APA: Copy

AMERIAN, MONERE, ZOLFAGHARI, POUNEH, SOHRABI, MOHAMMAD BAGHER, NIKKHESLAT, NASIM, YAHYAEI, ELAHEH, & HOSSAIN ZARGHARI, SIMA. (2016). EFFECTS OF NICOTINIC ACID AND SEVELAMER ON HYPERPHOSPHATEMIA IN THE HEMODIALYSIS PATIENTS: A DOUBLE BLIND CLINICAL TRIAL. KNOWLEDGE AND HEALTH, 1(1 ), 62-68. SID. https://sid.ir/paper/107958/en

Vancouver: Copy

AMERIAN MONERE, ZOLFAGHARI POUNEH, SOHRABI MOHAMMAD BAGHER, NIKKHESLAT NASIM, YAHYAEI ELAHEH, HOSSAIN ZARGHARI SIMA. EFFECTS OF NICOTINIC ACID AND SEVELAMER ON HYPERPHOSPHATEMIA IN THE HEMODIALYSIS PATIENTS: A DOUBLE BLIND CLINICAL TRIAL. KNOWLEDGE AND HEALTH[Internet]. 2016;1(1 ):62-68. Available from: https://sid.ir/paper/107958/en

IEEE: Copy

MONERE AMERIAN, POUNEH ZOLFAGHARI, MOHAMMAD BAGHER SOHRABI, NASIM NIKKHESLAT, ELAHEH YAHYAEI, and SIMA HOSSAIN ZARGHARI, “EFFECTS OF NICOTINIC ACID AND SEVELAMER ON HYPERPHOSPHATEMIA IN THE HEMODIALYSIS PATIENTS: A DOUBLE BLIND CLINICAL TRIAL,” KNOWLEDGE AND HEALTH, vol. 1, no. 1 , pp. 62–68, 2016, [Online]. Available: https://sid.ir/paper/107958/en

Related Journal Papers